Melanoma: A multidisciplinary approach for the general surgeon

Surgical Clinics of North America

Volumn 80, Issue 2, 2000, Pages 581-601

  Reeves, Mark E ^b   Coit, Daniel G ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GANGLIOSIDE GM2; GANGLIOSIDE GM2 KEYHOLE LIMPET HEMOCYANIN VACCINE; GMK VACCINE; HAPTEN; KEYHOLE LIMPET HEMOCYANIN; MELACINE; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; PHOSPHORYL LIPID A; QS 21; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE;

CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER SURVIVAL; CELL LYSATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; ELECTIVE SURGERY; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 0034000005     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70202-4     Document Type: Article

References (111)

1. S.S. Agarwala J.M. Kirkwood Adjuvant interferon treatment for melanoma Hematol Oncol Clin North Am 12 1998 823 833
2. S.S. Agarwala J.M. Kirkwood Adjuvant therapy of melanoma Semin Surg Oncol 14 1998 302 310
3. J.J. Albertini C.W. Cruse D. Rapaport Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma Ann Surg 223 1996 217 224
4. T.R. Ashworth A case of cancer in which cells similar to those in the tumours were seen in the blood after death Aust Med J 14 1869 146
5. C.M. Balch D.R. Murray C. Presant A randomized prospective comparison of BCG versus C. parvum adjuvant immunotherapy in melanoma patients with resected metastatic lymph nodes Proc Am Soc Clin Oncol 3 1984 263
6. C.M. Balch D.S. Reintgen J.M. Kirkwood Cutaneous melanoma DeVita V.T. Hellman S. Rosenberg S.A. Cancer: Principles and Practice of Oncology ed 5 1997 Lippincott-Raven Philadelphia 1947 1994
7. C.M. Balch R.V. Smalley A.A. Bartolucci A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): Prognostic factors analysis and preliminary results of immunotherapy Cancer 49 1982 1079 1084
8. C.M. Balch S.J. Soong A.A. Bartolucci Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger Ann Surg 224 1996 255 263
9. C.M. Balch S.J. Soong G.W. Milton A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia Ann Surg 196 1982 677 684
10. C.M. Balch S.J. Soong T.M. Murad A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II) Ann Surg 193 1981 377 388
11. C.M. Balch M.M. Urist C.P. Karakousis Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial Ann Surg 218 1993 262 267
12. A. Barth D.S. Hoon L.J. Foshag Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response Cancer Res 54 1994 3342 3345
13. Z. Battayani J.J. Grob L. Xerri Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma Arch Dermatol 131 1995 443 447
14. D. Berd Cancer vaccines: reborn or just recycled? Semin Oncol 25 1998 605 610
15. D. Berd J. Kairys C. Dunton Autologous, hapten-modified vaccine as a treatment for human cancers Semin Oncol 25 1998 646 653
16. Berd D. Maguire H.C. Jr L.M. Schuchter Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases J Clin Oncol 15 1997 2359 2370
17. S.C. Bieligk R. Ghossein S. Bhattacharya Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes Ann Surg Oncol 6 1999 232 240
18. M.S. Brady D.G. Coit Sentinel lymph node evaluation in melanoma Arch Dermatol 133 1997 1014 1020
19. P. Brossart U. Keilholz M. Willhauck Hematogenous spread of malignant melanoma cells in different stages of disease J Invest Dermatol 101 1993 887 889
20. F.M. Busch E.S. Sayegh Roentgenographic visualization of human testicular lymphatics: A preliminary report J Urol 89 1963 106 110
21. A.C. Buzaid M.I. Ross C.M. Balch Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system J Clin Oncol 15 1997 1039 1051
22. R.M. Cabanas An approach for the treatment of penile carcinoma Cancer 39 1977 456 466
23. C. Callery A.J. Cochran D.J. Roe Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes Ann Surg 196 1982 69 75
24. D. Campana C.H. Pui Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance Blood 85 1995 1416 1434
25. N. Cascinelli Evaluation of efficacy of adjuvant rIFNα 2A in melanoma patients with regional node metastases Proc Am Soc Clin Oncol 14 1995 410
26. N. Cascinelli Margin of resection in the management of primary melanoma Semin Surg Oncol 14 1998 272 275
27. N. Cascinelli R. Bufalino A. Morabito Results of adjuvant interferon study in WHO melanoma programme [letter] Lancet 343 1994 913 914
28. N. Cascinelli A. Morabito M. Santinami Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. WHO Melanoma Programme Lancet 351 1998 793 796
29. N. Cascinelli M. Vaglini M. Nava Prognosis of skin melanoma with regional node metastases (stage II) J Surg Oncol 25 1984 240 247
30. H. Cave C. Guidal P. Rohrlich Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes Blood 83 1994 1892 1902
31. A.D. Chan D.L. Morton Active immunotherapy with allogeneic tumor cell vaccines: present status Semin Oncol 25 1998 611 622
32. Y.T. Chen E. Stockert A. Jungbluth Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas Proc Natl Acad Sci U S A 93 1996 5915 5919
33. Y.T. Chen E. Stockert S. Tsang Immunophenotyping of melanomas for tyrosinase: Implications for vaccine development Proc Natl Acad Sci U S A 92 1995 8125 8129
34. W. Christopherson Cancer cells in the peripheral blood: A second look Acta Cytol 9 1965 169 174
35. B.M. Clary M.S. Brady J.J. Lewis Should frozen section analysis of the sentinel node be performed in patients with melanoma Eur J Nuc Med 26 suppl 1999 68
36. A.J. Cochran D.R. Wen D.L. Morton Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma: An immunohistological study Am J Surg Pathol 12 1988 612 618
37. D. Coit R. Ghossein V. Vlamis Prognostic significance of detection of tyrosinase mRNA in the peripheral blood and/or bone marrow of melanoma patients rendered surgically free of disease [abstract] Proc Am Soc Clin Oncol 17 1998 514
38. B.F. Cole R.D. Gelber J.M. Kirkwood Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study J Clin Oncol 14 1996 2666 2673
39. E.T. Creagan R.J. Dalton D.L. Ahmann Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 1995 2776 2783
40. B.M. Czarnetzki E. Macher S. Suciu Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781) Eur J Cancer 9 1993 1237 1242
41. S.S. Devesa W.J. Blot B.J. Stone Recent cancer trends in the United States J Natl Cancer Inst 87 1995 175 182
42. A.M. Eggermont Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma Eur J Cancer 34 suppl 3 1998 22 26
43. A.J. Foss M.J. Guille N.L. Occleston The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction Br J Cancer 72 1995 155 159
44. M. Gerhard H. Juhl H. Kalthoff Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction J Clin Oncol 12 1994 725 729
45. J.E. Gershenwald M.I. Colome J.E. Lee Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma J Clin Oncol 16 1998 2253 2260
46. J.E. Gershenwald W. Thompson P.F. Mansfield Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients J Clin Oncol 17 1999 976 983
47. R.A. Ghossein D. Coit M. Brennan Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma Clin Cancer Res 4 1998 419 428
48. R.A. Ghossein J. Rosai Polymerase chain reaction in the detection of micrometastases and circulating tumor cells Cancer 78 1996 10 16
49. H.J. Gray Relation of the lymphatic vessels to the spread of cancer Br J Surg 26 1939 462 495
50. B.E. Hillner J.M. Kirkwood M.B. Atkins Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684 J Clin Oncol 15 1997 2351 2358
51. S.N. Hochwald D.G. Coit Role of elective lymph node dissection in melanoma Semin Surg Oncol 14 1998 276 282
52. D.S. Hoon Y. Wang P.S. Dale Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay J Clin Oncol 13 1995 2109 2116
53. A.N. Houghton D. Mintzer C. Cordon-Cardo Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma Proc Natl Acad Sci U S A 82 1985 1242 1246
54. E.C. Hsueh A. Nizze R. Essner Adjuvant immunotherapy with polyvalent melanoma cell vaccine (PMCV) prolongs survival after complete resection of distant melanoma metastases Proc Am Soc Clin Oncol 16 1997 492
55. P.C. Jones L.L. Sze P.Y. Liu Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen J Natl Cancer Inst 66 1981 249 254
56. Karpoff H, Ghossein R, Cheung I, et al: Tyrosinase and GAGE mRNA in peripheral blood and bone marrow predict outcome in stage III melanoma patients rendered free of disease. Presented at the 52nd Annual Cancer Symposium, Society of Surgical Oncology. Orlando, FL, March 5, 1999, p 19
57. M.C. Kelley D.W. Ollila D.L. Morton Lymphatic mapping and sentinel lymphadenectomy for melanoma Semin Surg Oncol 14 1998 283 290
58. J.M. Kirkwood J. Ibrahim V. Sondak Preliminary analysis of the E1690/S9111/C9190 Intergroup Postoperative Adjuvant Trial of high- and low-dose IFNα2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma [abstract] Proc Am Soc Clin Oncol 18 1999 537
59. J.M. Kirkwood M.H. Strawderman M.S. Ernstoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
60. T. Komeda Y. Fukuda T. Sando Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood Cancer 75 1995 2214 2219
61. D.N. Krag S.J. Meijer D.L. Weaver Minimal-access surgery for staging of malignant melanoma Arch Surg 130 1995 654 658 discussion 659–660
62. U. Kunter J. Buer M. Probst Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma J Natl Cancer Inst 88 1996 590 594
63. S.H. Landis T. Murray S. Bolden Cancer statistics, 1999 CA Cancer J Clin 49 1999 8 31
64. M.S. Lee K.S. Chang F. Cabanillas Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification Science 237 1987 175 178
65. S.P. Leong I. Steinmetz F.A. Habib Optimal selective sentinel lymph node dissection in primary malignant melanoma Arch Surg 132 1997 666 672 discussion 673
66. M.K. Lingam R.M. Mackie A.J. McKay Intraoperative identification of sentinel lymph node in patients with malignant melanoma Br J Cancer 75 1997 1505 1508
67. P. Livingston Ganglioside vaccines with emphasis on GM2 Semin Oncol 25 1998 636 645
68. P.O. Livingston Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines Immunol Rev 145 1995 147 166
69. P.O. Livingston S. Adluri F. Helling Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma Vaccine 12 1994 1275 1280
70. P.O. Livingston G.Y. Wong S. Adluri Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036 1044
71. Malignant Melanoma of the Skin Fleming I.D. Cooper J.S. Henson D.E. AJCC Cancer Staging Manual vol 5 1997 Lippincott-Raven Philadelphia 163 170
72. F.M. Marincola Y.M. Hijazi P. Fetsch Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions J Immunother Emphasis Tumor Immunol 19 1996 192 205
73. S. Martin H.U. Weltzien T cell recognition of haptens, a molecular view Int Arch Allergy Immunol 104 1994 10 16
74. M.J. Mastrangelo D. Berd Maguire H. Jr The immunoaugmenting effects of cancer chemotherapeutic agents Semin Oncol 13 1986 186 194
75. B. Mellado D. Colomer T. Castel Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis J Clin Oncol 14 1996 2091 2097
76. J.L. Messina L.F. Glass Pathologic examination of the sentinel lymph node J Fla Med Assoc 84 1997 153 156
77. M.S. Mitchell Perspective on allogeneic melanoma lysates in active specific immunotherapy Semin Oncol 25 1998 623 635
78. M.S. Mitchell J. Jakowatz W. Harel Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma J Clin Oncol 12 1994 402 411
79. Y. Miyajima K. Kato S. Numata Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA Cancer 75 1995 2757 2761
80. D.L. Morton A. Nizze D.S.B. Hoon Improved survival of advanced stage IV melanoma following active immunotherapy: Correlation with immune response to melanoma vaccine Proc Am Soc Clin Oncol 12 1993 391
81. D.L. Morton D.R. Wen L.J. Foshag Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck J Clin Oncol 11 1993 1751 1756
82. D.L. Morton D.R. Wen J.H. Wong Technical details of intraoperative lymphatic mapping for early stage melanoma Arch Surg 127 1992 392 399
83. T.J. Moss D.G. Sanders Detection of neuroblastoma cells in blood J Clin Oncol 8 1990 736 740
84. A. Mudun D.R. Murray S.C. Herda Early stage melanoma: Lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe Radiology 199 1996 171 175
85. National Institutes of Health Consensus conference: Diagnosis and treatment of early melanoma JAMA 268 1992 1314 1319
86. J. Norman C.W. Cruse C. Espinosa Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma Am J Surg 162 1991 432 437
87. D.W. Ollila M.C. Kelley G. Gammon Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients Semin Surg Oncol 14 1998 328 336
88. S. Pestka J.A. Langer K.C. Zoon Interferons and their actions Annu Rev Biochem 56 1987 727 777
89. G. Prota Recent advances in the chemistry of melanogenesis in mammals J Invest Dermatol 75 1980 122 127
90. W.H. Redding R.C. Coombes P. Monaghan Detection of micrometastases in patients with primary breast cancer Lancet 2 1983 1271 1274
91. U. Reinhold H.C. Ludtke-Handjery S. Schnautz The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression J Invest Dermatol 108 1997 166 169
92. D. Reintgen C.W. Cruse K. Wells The orderly progression of melanoma nodal metastases Ann Surg 220 1994 759 767
93. D.S. Reintgen A. Brobeil Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma Hematol Oncol Clin North Am 12 1998 807 821 vii
94. M.I. Ross D.S. Reintgen Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases Eur J Cancer 34 suppl 3 1998 7 11
95. S.C. Shivers X. Wang W. Li Molecular staging of malignant melanoma: Correlation with clinical outcome JAMA 280 1998 1410 1415
96. F.H. Sim W.F. Taylor J.C. Ivins A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: Preliminary results Cancer 41 1978 948 956
97. B. Smith P. Selby J. Southgate Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction Lancet 338 1991 1227 1229
98. R.A. Stahel M. Mabry A.T. Skarin Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody J Clin Oncol 3 1985 455 461
99. G.R. Stark I.M. Kerr B.R. Williams How cells respond to interferons Annu Rev Biochem 67 1998 227 264
100. J.F. Thompson W.H. McCarthy C.M. Bosch Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes Melanoma Res 5 1995 255 260
101. R.F. Uren R.B. Howman-Giles H.M. Shaw Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node J Nucl Med 34 1993 1435 1440
102. U. Veronesi J. Adamus C. Aubert A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma N Engl J Med 307 1982 913 916
103. U. Veronesi J. Adamus D.C. Bandiera Inefficacy of immediate node dissection in stage 1 melanoma of the limbs N Engl J Med 297 1977 627 630
104. U. Veronesi J. Adamus D.C. Bandiera Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities Cancer 49 1982 2420 2430
105. U. Veronesi N. Cascinelli Narrow excision (1-cm margin): A safe procedure for thin cutaneous melanoma Arch Surg 126 1991 438 441
106. M.K. Wallack S.D. Scoggin M. Sivanandham Active specific immunotherapy with vaccinia melanoma oncolysate Mt Sinai J Med 59 1992 227 233
107. M.K. Wallack M. Sivanandham C.M. Balch A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma Cancer 75 1995 34 42
108. A.E. Walts J.W. Said I.P. Shintaku Cytodiagnosis of malignant melanoma: Immunoperoxidase staining with HMB-45 antibody as an aid to diagnosis Am J Clin Pathol 90 1988 77 80
109. X. Wang R. Heller N. VanVoorhis Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma Ann Surg 220 1994 768 774
110. J.D. Wolchok P.O. Livingston A.N. Houghton Vaccines and other adjuvant therapies for melanoma Hematol Oncol Clin North Am 12 1998 835 848
111. J.H. Wong L.A. Cagle D.L. Morton Lymphatic drainage of skin to a sentinel lymph node in a feline model Ann Surg 214 1991 637 641